Text Size

Site Search powered by Ajax

Sodium Polystyrene Sulfonate

Sodium Polystyrene Sulfonate

Generic and Trade Names

Sodium Polystyrene Sulfonate SPS, Kayexalate



Description:

Sodium polystyrene sulfonate is a prescription drug classified as a potassium-removing resin. It is used to reduce high levels of potassium in the blood (hyperkalemia).

Sodium polystyrene sulfonate acts in the large intestine by exchanging sodium ion for potassium ions, thus decreasing the amount of potassium in the body. (Facts and Comparisons 1999)

Nutritional Considerations:

High sodium content, use with caution in patients with congestive heart failure, severe hypertension or fluid retentive individuals. (Facts and Comparisons 1999)

Electrolytes: calcium, magnesium and potassium can become unbalanced, monitor electrolytes carefully. (Pronsky 1999)

Herbal Considerations:

Because licorice root can affect blood serum potassium levels, it may potentiate the hypokalemic property of sodium polystyrene sulfonate. (Brinker 1998)

References

Angel, J.E. 1983. Physicians Desk Reference. Medical Economics Company, Inc. Oradell, New Jersey.

Angelo-Nielsen K & Ringsted C: Resonium A-induced hypocalcaemic tetany. Dan Med Bull 1983; 30:348-349.

Berlyne GM, Janabi K & Shaw AB: Dangers of resonium A in the treatment of hyperkalemia in renal failure. Lancet 1966; 1:167-169.

Brinker, Francis Herb Contraindications and Drug Interactions, Eclectic Medical Publications, 1998.

Cacioppo & Hollander: Orange juice treated with exchange resin. N Engl J Med 1972; 287:361.

Facts and Comparisons, Clinisphere 2.0, Wolters Kluwer Company, 1999.

Product Information: Kayexalate(R), sodium polystyrene sulfonate. Sanofi Winthrop Pharmaceuticals, New York, NY, 1994.

Pronsky, Zaneta. Food Medication Interactions. 11th edition. 1999.

Schroeder ET: Alkalosis resulting from combined administration of a "non-systemic" antacid and a cation-exchange resin. Gastroenterology 1969; 56:868.

Townsend CM, Remmers AR Jr, Sarles HE et al: Intestinal obstruction from medication bezoar in patients with renal failure. N Engl J Med 1973; 288:1058-1059.

Main Menu